Susquehanna International Group
CERE

Susquehanna International Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Susquehanna International Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-493,400
Closed -$20.2M – 13386
2024
Q2 		$20.2M Buy
493,400
+83,500
+20% +$3.48M ﹤0.01% 1715
2024
Q1 		$17.3M Buy
409,900
+60,300
+17% +$2.53M ﹤0.01% 1937
2023
Q4 		$14.8M Buy
349,600
+182,300
+109% +$5.24M ﹤0.01% 2139
2023
Q3 		$3.65M Sell
167,300
-45,200
-21% -$1.13M ﹤0.01% 4058
2023
Q2 		$6.76M Sell
212,500
-45,100
-18% -$1.38M ﹤0.01% 3052
2023
Q1 		$6.28M Buy
257,600
+33,100
+15% +$971K ﹤0.01% 3113
2022
Q4 		$7.08M Sell
224,500
-37,500
-14% -$1.06M ﹤0.01% 2731
2022
Q3 		$7.4M Buy
262,000
+118,100
+82% +$3.52M ﹤0.01% 2575
2022
Q2 		$3.81M Buy
143,900
+68,500
+91% +$1.94M ﹤0.01% 3659
2022
Q1 		$2.64M Sell
75,400
-53,700
-42% -$1.57M ﹤0.01% 4865
2021
Q4 		$4.18M Sell
129,100
-44,400
-26% -$1.57M ﹤0.01% 4051
2021
Q3 		$5.12M Buy
173,500
+60,700
+54% +$1.7M ﹤0.01% 3915
2021
Q2 		$2.89M Buy
+112,800
New +$1.61M ﹤0.01% 5105

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Susquehanna International Group's CERE Position: Q3 2024 in Review

Susquehanna International Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 108,832 shares — an estimated $4.45M sold.

Susquehanna International Group first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $6.17M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Susquehanna International Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 108,832 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $4.45M.
  • Susquehanna International Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Susquehanna International Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $6.17M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.